Loading
Countries buying cancer drugs alone pay more and face shortages. Buying together, as they already do for childhood cancer drugs and vaccines, cuts prices and secures supply.
The WHO and St Jude Global Platform for Access to Childhood Cancer Medicines (2021) pools demand across countries for paediatric essential medicines; PAHO's Strategic Fund and Gavi do the same for other products. Adult essential oncology medicines on the WHO Model List (cisplatin, carboplatin, paclitaxel, docetaxel, tamoxifen, letrozole, imatinib, trastuzumab biosimilars and others) are procured nationally at widely varying prices. The proposal is a pooled procurement mechanism for these products covering low- and lower-middle-income countries, with multi-year volume guarantees, quality prequalification and a buffer stock against shortages.
Shares Imatinib, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
Shares Imatinib, Prices and value, Trastuzumab, Most of the world has almost no cancer care.
Shares Imatinib, Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Prices and value, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Imatinib, Prices and value, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel.
Shares Prices and value, Trastuzumab, Most of the world has almost no cancer care.
Shares Prices and value, Most of the world has almost no cancer care.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/